Aspirin Discontinuation Syndromes: Clinical Implications of Basic Research Studies
Abrupt discontinuation of many drugs used in medicine causes withdrawal syndromes, some of which can be fatal. Discontinuation of a number of cardiovascular drugs can increase the risk of cardiovascular events. Whereas aspirin administration is known to decrease the risk of vascular ischemic problem...
Gespeichert in:
| Veröffentlicht in: | American journal of cardiovascular drugs : drugs, devices, and other interventions devices, and other interventions, 2013-12, Vol.13 (6), p.377-384 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 384 |
|---|---|
| container_issue | 6 |
| container_start_page | 377 |
| container_title | American journal of cardiovascular drugs : drugs, devices, and other interventions |
| container_volume | 13 |
| creator | Doutremepuich, Christian Aguejouf, Omar Desplat, Vanessa Eizayaga, Francisco X. |
| description | Abrupt discontinuation of many drugs used in medicine causes withdrawal syndromes, some of which can be fatal. Discontinuation of a number of cardiovascular drugs can increase the risk of cardiovascular events. Whereas aspirin administration is known to decrease the risk of vascular ischemic problems, aspirin withdrawal may temporarily increase the risk of thrombotic events. Indeed, aspirin withdrawal has been associated with an increased risk of thrombosis both in clinical and fundamental research studies. Such complications occur within the first month after interrupting aspirin therapy and their mechanism remains unexplained. We have previously demonstrated that aspirin, when injected as a single high dose (100 mg/kg), induces a prothrombotic state in the rat, similar to that described above, 8 and 10 days after administration. This effect in the rat may be reproduced 1 hour after a single injection of ultra-low-dose aspirin. Caution is therefore required regarding the possibility of drug discontinuation effects within the framework of drug safety evaluation. |
| doi_str_mv | 10.1007/s40256-013-0044-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1501373592</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3227283981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-7ac773c5eb477846ecb2213878db6b0822ea00778890d8126dfadbb45187f5c83</originalsourceid><addsrcrecordid>eNp1kF9LwzAUxYMobk4_gC8S8DmapEmT-jbnv8FA2BR8C2maakbX1qR92Lc3s1N88eleuOecy_kBcE7wFcFYXAeGKU8RJgnCmDFEDsCYEJEhIsXb4ffOUUKFGIGTENYYE0FFdgxGlGHGMy7HYDkNrfOuhncumKbuXN3rzjU1XG3rwjcbG27grHK1M7qC801bxWV3D7Ap4a0OzsClDVZ78wFXXV84G07BUamrYM_2cwJeH-5fZk9o8fw4n00XyCSCdkhoI0RiuM2ZEJKl1uSUkkQKWeRpjiWlVseSQsoMF5LQtCh1keeMx3IlNzKZgMsht_XNZ29Dp9ZN7-v4UhEemYiEZzSqyKAyvgnB21K13m203yqC1Y6iGiiq6FA7iopEz8U-uc83tvh1_GCLAjoIQjzV79b_ef1v6hdQNXx4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1501373592</pqid></control><display><type>article</type><title>Aspirin Discontinuation Syndromes: Clinical Implications of Basic Research Studies</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Doutremepuich, Christian ; Aguejouf, Omar ; Desplat, Vanessa ; Eizayaga, Francisco X.</creator><creatorcontrib>Doutremepuich, Christian ; Aguejouf, Omar ; Desplat, Vanessa ; Eizayaga, Francisco X.</creatorcontrib><description>Abrupt discontinuation of many drugs used in medicine causes withdrawal syndromes, some of which can be fatal. Discontinuation of a number of cardiovascular drugs can increase the risk of cardiovascular events. Whereas aspirin administration is known to decrease the risk of vascular ischemic problems, aspirin withdrawal may temporarily increase the risk of thrombotic events. Indeed, aspirin withdrawal has been associated with an increased risk of thrombosis both in clinical and fundamental research studies. Such complications occur within the first month after interrupting aspirin therapy and their mechanism remains unexplained. We have previously demonstrated that aspirin, when injected as a single high dose (100 mg/kg), induces a prothrombotic state in the rat, similar to that described above, 8 and 10 days after administration. This effect in the rat may be reproduced 1 hour after a single injection of ultra-low-dose aspirin. Caution is therefore required regarding the possibility of drug discontinuation effects within the framework of drug safety evaluation.</description><identifier>ISSN: 1175-3277</identifier><identifier>EISSN: 1179-187X</identifier><identifier>DOI: 10.1007/s40256-013-0044-1</identifier><identifier>PMID: 24045958</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Animals ; Aspirin - adverse effects ; Biomedical Research - methods ; Cardiology ; Dose-Response Relationship, Drug ; Leading Article ; Male ; Medicine ; Medicine & Public Health ; Mice ; Mice, Knockout ; Pharmacology/Toxicology ; Pharmacotherapy ; Rats ; Substance Withdrawal Syndrome - metabolism ; Substance Withdrawal Syndrome - pathology ; Thrombosis - metabolism ; Thrombosis - pathology</subject><ispartof>American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013-12, Vol.13 (6), p.377-384</ispartof><rights>Springer International Publishing Switzerland 2013</rights><rights>Copyright Wolters Kluwer Health Adis International Dec 2013</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-7ac773c5eb477846ecb2213878db6b0822ea00778890d8126dfadbb45187f5c83</citedby><cites>FETCH-LOGICAL-c372t-7ac773c5eb477846ecb2213878db6b0822ea00778890d8126dfadbb45187f5c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40256-013-0044-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40256-013-0044-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24045958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Doutremepuich, Christian</creatorcontrib><creatorcontrib>Aguejouf, Omar</creatorcontrib><creatorcontrib>Desplat, Vanessa</creatorcontrib><creatorcontrib>Eizayaga, Francisco X.</creatorcontrib><title>Aspirin Discontinuation Syndromes: Clinical Implications of Basic Research Studies</title><title>American journal of cardiovascular drugs : drugs, devices, and other interventions</title><addtitle>Am J Cardiovasc Drugs</addtitle><addtitle>Am J Cardiovasc Drugs</addtitle><description>Abrupt discontinuation of many drugs used in medicine causes withdrawal syndromes, some of which can be fatal. Discontinuation of a number of cardiovascular drugs can increase the risk of cardiovascular events. Whereas aspirin administration is known to decrease the risk of vascular ischemic problems, aspirin withdrawal may temporarily increase the risk of thrombotic events. Indeed, aspirin withdrawal has been associated with an increased risk of thrombosis both in clinical and fundamental research studies. Such complications occur within the first month after interrupting aspirin therapy and their mechanism remains unexplained. We have previously demonstrated that aspirin, when injected as a single high dose (100 mg/kg), induces a prothrombotic state in the rat, similar to that described above, 8 and 10 days after administration. This effect in the rat may be reproduced 1 hour after a single injection of ultra-low-dose aspirin. Caution is therefore required regarding the possibility of drug discontinuation effects within the framework of drug safety evaluation.</description><subject>Animals</subject><subject>Aspirin - adverse effects</subject><subject>Biomedical Research - methods</subject><subject>Cardiology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Leading Article</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Rats</subject><subject>Substance Withdrawal Syndrome - metabolism</subject><subject>Substance Withdrawal Syndrome - pathology</subject><subject>Thrombosis - metabolism</subject><subject>Thrombosis - pathology</subject><issn>1175-3277</issn><issn>1179-187X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kF9LwzAUxYMobk4_gC8S8DmapEmT-jbnv8FA2BR8C2maakbX1qR92Lc3s1N88eleuOecy_kBcE7wFcFYXAeGKU8RJgnCmDFEDsCYEJEhIsXb4ffOUUKFGIGTENYYE0FFdgxGlGHGMy7HYDkNrfOuhncumKbuXN3rzjU1XG3rwjcbG27grHK1M7qC801bxWV3D7Ap4a0OzsClDVZ78wFXXV84G07BUamrYM_2cwJeH-5fZk9o8fw4n00XyCSCdkhoI0RiuM2ZEJKl1uSUkkQKWeRpjiWlVseSQsoMF5LQtCh1keeMx3IlNzKZgMsht_XNZ29Dp9ZN7-v4UhEemYiEZzSqyKAyvgnB21K13m203yqC1Y6iGiiq6FA7iopEz8U-uc83tvh1_GCLAjoIQjzV79b_ef1v6hdQNXx4</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Doutremepuich, Christian</creator><creator>Aguejouf, Omar</creator><creator>Desplat, Vanessa</creator><creator>Eizayaga, Francisco X.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20131201</creationdate><title>Aspirin Discontinuation Syndromes: Clinical Implications of Basic Research Studies</title><author>Doutremepuich, Christian ; Aguejouf, Omar ; Desplat, Vanessa ; Eizayaga, Francisco X.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-7ac773c5eb477846ecb2213878db6b0822ea00778890d8126dfadbb45187f5c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Aspirin - adverse effects</topic><topic>Biomedical Research - methods</topic><topic>Cardiology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Leading Article</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Rats</topic><topic>Substance Withdrawal Syndrome - metabolism</topic><topic>Substance Withdrawal Syndrome - pathology</topic><topic>Thrombosis - metabolism</topic><topic>Thrombosis - pathology</topic><toplevel>online_resources</toplevel><creatorcontrib>Doutremepuich, Christian</creatorcontrib><creatorcontrib>Aguejouf, Omar</creatorcontrib><creatorcontrib>Desplat, Vanessa</creatorcontrib><creatorcontrib>Eizayaga, Francisco X.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of cardiovascular drugs : drugs, devices, and other interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Doutremepuich, Christian</au><au>Aguejouf, Omar</au><au>Desplat, Vanessa</au><au>Eizayaga, Francisco X.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aspirin Discontinuation Syndromes: Clinical Implications of Basic Research Studies</atitle><jtitle>American journal of cardiovascular drugs : drugs, devices, and other interventions</jtitle><stitle>Am J Cardiovasc Drugs</stitle><addtitle>Am J Cardiovasc Drugs</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>13</volume><issue>6</issue><spage>377</spage><epage>384</epage><pages>377-384</pages><issn>1175-3277</issn><eissn>1179-187X</eissn><abstract>Abrupt discontinuation of many drugs used in medicine causes withdrawal syndromes, some of which can be fatal. Discontinuation of a number of cardiovascular drugs can increase the risk of cardiovascular events. Whereas aspirin administration is known to decrease the risk of vascular ischemic problems, aspirin withdrawal may temporarily increase the risk of thrombotic events. Indeed, aspirin withdrawal has been associated with an increased risk of thrombosis both in clinical and fundamental research studies. Such complications occur within the first month after interrupting aspirin therapy and their mechanism remains unexplained. We have previously demonstrated that aspirin, when injected as a single high dose (100 mg/kg), induces a prothrombotic state in the rat, similar to that described above, 8 and 10 days after administration. This effect in the rat may be reproduced 1 hour after a single injection of ultra-low-dose aspirin. Caution is therefore required regarding the possibility of drug discontinuation effects within the framework of drug safety evaluation.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>24045958</pmid><doi>10.1007/s40256-013-0044-1</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1175-3277 |
| ispartof | American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013-12, Vol.13 (6), p.377-384 |
| issn | 1175-3277 1179-187X |
| language | eng |
| recordid | cdi_proquest_journals_1501373592 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Animals Aspirin - adverse effects Biomedical Research - methods Cardiology Dose-Response Relationship, Drug Leading Article Male Medicine Medicine & Public Health Mice Mice, Knockout Pharmacology/Toxicology Pharmacotherapy Rats Substance Withdrawal Syndrome - metabolism Substance Withdrawal Syndrome - pathology Thrombosis - metabolism Thrombosis - pathology |
| title | Aspirin Discontinuation Syndromes: Clinical Implications of Basic Research Studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T23%3A35%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aspirin%20Discontinuation%20Syndromes:%20Clinical%20Implications%20of%20Basic%20Research%20Studies&rft.jtitle=American%20journal%20of%20cardiovascular%20drugs%20:%20drugs,%20devices,%20and%20other%20interventions&rft.au=Doutremepuich,%20Christian&rft.date=2013-12-01&rft.volume=13&rft.issue=6&rft.spage=377&rft.epage=384&rft.pages=377-384&rft.issn=1175-3277&rft.eissn=1179-187X&rft_id=info:doi/10.1007/s40256-013-0044-1&rft_dat=%3Cproquest_cross%3E3227283981%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1501373592&rft_id=info:pmid/24045958&rfr_iscdi=true |